Tri:ChAd:TB
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Read MorePNx6
PNx6 is a modular, self-assembling and self-adjuvanting peptide-based vaccine candidate that is cold-chain independent. Each peptide building blocks consist of a linear arrangement comprising a 15-leucine (15L) self-assembly inducer moiety, a 15 amino acid Mtb epitope and a 9 amino acids HLA-E binding moiety, with each moiety separated by a triple lysine spacer.
Read MoreSeV986A
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Read MoremRNA-Rv1387-Rv0287-Rv1788
The vaccine consists of three antigens delivered with the mRNA platform. Monovalent antigens were cloned into mRNA constructs containing a 5’ cap, 5’ untranslated region (UTR), 3’ UTR, and a polyadenylation signal, subjected to in vitro transcription using N1-methylpseudouridine, and encapsulated in lipid nanoparticles containing ALC-0315, 18:1 (Δ9-Cis) PE (DOPE), cholesterol, and 14:0 PEG2000 PE.
Read MorerBCG-LTAK63
rBCG-LTAK63 is an unmarked recombinant BCG strain expressing the subunit A of detoxified E. coli Heat-Labile Toxin (LTAK63) as adjuvant. rBCG-LTAK63 induced protection superior to standard BCG, through enhanced and regulated Th1/Th17 responses, and both early effector and long-term TRM cell responses with reduced lung inflammation and improved immunopathological control.
Read More